What is Ani Pharmaceuticals Inc worth?
With the base-case assumptions below, a discounted cash flow model on Ani Pharmaceuticals Inc's reported free cash flow gives $269.52 per share. The share price was $74.00 on September 25, 2026, 73% below that value.
Inputs from the filings
Three sets of assumptions
| Case | Growth yrs 1-5 | Discount rate | Value per share | Value vs price |
|---|---|---|---|---|
| Bear | 10.0% | 10.0% | $164.84 | +123% |
| Base | 15.0% | 9.0% | $269.52 | +264% |
| Bull | 20.0% | 8.0% | $464.42 | +528% |
Sensitivity: base case value per share
| 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | |
|---|---|---|---|---|---|
| 7.0% | $348.77 | $373.48 | $403.68 | $441.43 | $489.97 |
| 8.0% | $289.23 | $305.26 | $324.20 | $346.92 | $374.70 |
| 9.0% | $245.92 | $256.88 | $269.52 | $284.27 | $301.70 |
| 10.0% | $213.08 | $220.87 | $229.70 | $239.79 | $251.43 |
| 11.0% | $187.38 | $193.09 | $199.47 | $206.65 | $214.79 |
Where the presets come from
Base: years 1 to 5 grow at Ani Pharmaceuticals Inc's revenue growth rate over the last 5 fiscal years (33.5% a year), held between -5% and 15%. Years 6 to 10 grow halfway between that and the long-run rate of 2.5%. Future cash is discounted at 9% a year.
Bear: 5 points less growth, 2% long-run growth, 10% discount rate. Bull: 5 points more growth (at most 25%), 3% long-run growth, 8% discount rate.
Value per share = (present value of 10 years of free cash flow + present value of everything after + cash - debt) / diluted shares.
This is a model run on assumptions, not a recommendation or a price target. Small changes in the discount rate or growth move the result a lot, as the table above shows. Change them yourself in the calculator.
Adjust the assumptions
Move the sliders for growth, long-run growth and discount rate, or switch to average free cash flow, and see the value per share change.
Adjust the assumptions